Company Overview and News

 
Government wants power to stop sale of big infrastructure to overseas buyers

5h nzherald.co.nz
Associate Finance Minister David Parker today announced the next phase of overseas investment rule reviews, following the house sale ban which takes effect from next week.
AIA FBU FBU AIA FCREY ACKDF FRCEF AUKNY

19
Deals of the day-Mergers and acquisitions

16h reuters
Oct 15 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday:
FOX FBU STAN FCREY FRCEF FBU 580001 STAB STAN EPW STAC 2888 SCBFF AAPL GNC HRS IOF FOXA DIS

19
Deals of the day-Mergers and acquisitions

20h reuters
Oct 15 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 10.00 GMT on Monday:
FOX FBU STAN FCREY FRCEF FBU 580001 STAB STAN EPW STAC 2888 SCBFF AAPL GNC HRS IOF FOXA DIS

 
Fletcher gives up on Steel & Tube deal

2018-10-14 nzherald.co.nz
Fletcher Building won't keep chasing Steel & Tube Holdings after failing to win over the board with its latest offer.
FBU FBU FCREY FRCEF

 
Fletcher Building revises initial offer to buy Steel & Tube

2018-10-14 radionz.co.nz
Fletcher Building has lifted its non-binding takeover offer for Steel & Tube by 12 percent, but the board still thinks it is too low.
FBU FBU FCREY FRCEF

 
Fletcher ups bid, Steel & Tube remains wary

2018-10-14 nzherald.co.nz
Steel & Tube Holdings hasn't been won over by an increased takeover offer from Fletcher Building but will hire an independent expert to review the bid.
FBU FBU FCREY FRCEF

 
Fletcher and Ngāti Whātua start work on 239-home Hobsonville scheme

2018-10-14 nzherald.co.nz
Fletcher Building and Ngāti Whātua o Kaipara say work has started a new 239-residence subdivision on Clark Rd at Hobsonville in Auckland's northwest.
FBU FBU FCREY FRCEF

 
The interview: Bruce Cotterill - Talk to get message across

2018-10-12 nzherald.co.nz
Bruce Cotterill doesn't do start-ups, or "unicorns", or any of the other types of corporate vehicles with a funky name.
YLWDF FBU FBU FCREY Y FRCEF YLWWF

 
Restaurant Brands leads NZ shares lower

2018-10-09 nzherald.co.nz
New Zealand shares fell for a seventh day. Rising US bond yields kept a lid on equity markets across Asia, weighing on growth-orientated stocks such as A2 Milk Co and Pushpay Holdings.
AIR FCREY ZNRGF NZTCF RYM ACKDF ANZFY AUKNY AIZ SKT ZNZ SYKWF PPSHY SKKTY SML AIA FBU RHCGF SPKKY NZTCY SPK ZEL FRCEF AIA FBU ANZLY RYHTY ANZFF MEZ

 
Fletcher faces double hurdle in bid for Steel & Tube

2018-10-07 nzherald.co.nz
Fletcher Building may have to consider upping its offer for Steel & Tube, but the biggest hurdle for the construction giant may be gaining Commerce Commission clearance.
FBU FBU FCREY FRCEF

 
Analysts divided on Fletcher's $282m steel takeover: The case for and against

2018-10-05 nzherald.co.nz
Analysts are divided about Fletcher Building's proposed $282 million takeover of Steel & Tube: one cautiously supports the deal but is worried about potential hurdles like the Commerce Commission, another robustly opposes it for three reasons and a third says it will be strategically positive.
FBU FBU FCREY FRCEF

 
NZ shares fall; Genesis, A2 Milk drop

2018-10-04 nzherald.co.nz
New Zealand shares fell for a fourth day as A2 Milk Co remains out of favour after recent selling by its chief executive and a director. Genesis Energy and Auckland International Airport also declined after shedding rights to dividend payments.
CEN AIA FBU RHCGF FCREY CMO RYM ACKDF FRCEF AUKNY COENY KWIPF COENF GNE AIA PPSHY FBU RYHTY CEN GNE MEZ GEL

23
Deals of the day-Mergers and acquisitions

2018-10-03 reuters
Oct 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday:
FOX FBU GEC GE MYGSF XOM MYRSY MEG FCREY HUSKF FRCEF HSE MYR BHI BTU VCX CNRAF FBU MEGEF GNE BTUUQ MRO FOXA

 
Fletcher Building makes bid to buy Steel and Tube

2018-10-03 radionz.co.nz
Fletcher Building is looking to buy building products company Steel and Tube, but there has been a quick push back from the target company.
FBU FBU FCREY FRCEF

 
Steel & Tube receives $282 million takeover offer from Fletcher Building

2018-10-02 nzherald.co.nz
Steel & Tube's said it had received a takeover offer form Fletcher Building at $1.70 a share, which it said "significantly undervalues" the company.
FBU FBU FCREY FRCEF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...